Martidex
Marticeed
Martivetlox
Composition :
Each ml contains
Dexamethasone sodium phosphate 1.32 mg
Dexamethasone phenylpropionate 2.67 mg
Properties:
Dexamethasone is a highly potent corticosteroid. It has minimal mineralocorticosteroid activity and potent glucocorticosteroid activity. Dexamethasone has gluconeogenic, anti-inflammatory, anti-allergenic activity and it induces parturition. Dexamethasone preparation with a rapid onset of activity and a relatively long duration of action. It contains the disodium phosphate ester and phenylpropionate ester of dexamethasone.
Indications:
The product is indicated for use as an anti-inflammatory and anti-allergic agent in horses, cattle, dogs and cats, and for the treatment of primary ketosis in cattle. The product can also be used to induce parturition in cattle.
Target Species:
Horses, cattle, dogs and cats.
Dose for active ingredient:
Cattle and Horses : Dexamethasone sodium phosphate 1.32 mg and Dexamethasone phenylpropionate 2.67 mg / 50 kg BW
Dogs and cats : Dexamethasone sodium phosphate 1.32 mg and Dexamethasone phenylpropionate 2.67 mg / 20 kg BW
Dose for whole product:
Cattle and Horses : 1 ml per 50 kg body weight by IM Injection
Dogs and cats : 0.5 per10 kg body weight by IM Injection
Warnings:
Don’t use in Domestic animals neonates, Shake vial well before use
Withdrawal Periods:
Cattle:
Meat – 63 days
Milk – 144 hours
Contra-indications
Except in emergency situations the product should not be used in animals suffering from diabetes, chronic nephritis, renal disease, congestive heart failure, osteoporosis and in viral infections during the viraemic stage.
Side-Effects:
Anti-inflammatory corticosteroids, such as dexamethasone, are known to exert a wide range of side-effects. Whilst single high doses are generally well tolerated, they may induce severe side-effects in long term use and when esters possessing a long duration of action are administered. Dosage in medium to long term use should therefore generally be kept to the minimum necessary to control symptoms.
Steroids themselves, during treatment, may cause Cushingoid symptoms involving significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g. redistribution of body fat, muscle weakness and wastage and osteoporosis may result. During therapy effective doses suppress the hypothalamo-pituitreal-adrenal axis. Following cessation of treatment, symptoms of adrenal insufficiency extending to adrenocortical atrophy can arise and this may render the animal unable to deal adequately with stressful situations. Consideration should therefore be given to means of minimising problems of adrenal insufficiency following the withdrawal of treatment, eg dosing to coincide with the time of the endogenous cortisol peak (ie in the morning with regard to dogs and the evening re cats) and a gradual reduction of dosage (for further discussion see standard texts).
Storage:
Store in dry dark and place at temperature not exceeding to 30 o.
Packaging:
Vial of 50,100 and 250 ml
